ログイン
ランキング
お知らせ
ログイン
文献詳細
増大特集 中枢神経の自己免疫性・炎症性疾患ハンドブック
第2章 疾患各論
文献概要
視神経脊髄炎関連疾患（NMOSD）は，主に視神経炎，脊髄炎や最後野症候群をきたす中枢性自己免疫疾患である。抗アクアポリン4（AQP4）抗体が関与して補体介在性にアストロサイト傷害をきたす特徴は従来の多発性硬化症（MS）とは病態が異なる。治療においてもMSの疾患修飾薬は無効ないし増悪することが知られ，従来NMOSDでは低用量ステロイドや免疫抑制剤が使用され，近年は補体やB細胞系を抑える生物学的製剤が相次いで登場している。
参考文献
1）Kuroiwa Y, Igata A, Itahara K, Koshijima S, Tsubaki T: Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology 25: 845-851, 1975
2）Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53: 1107-1114, 1999
3）Misu T, Fujihara K, Nakashima I, Miyazawa I, Okita N, et al: Pure optic-spinal form of multiple sclerosis in Japan. Brain 125: 2460-2468, 2002
4）Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004
5）Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, et al: Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224-1234, 2007
6）Shimizu Y, Yokoyama K, Misu T, Takahashi T, Fujihara K, et al: Development of extensive brain lesions following inferferon beta therapy in relapsing neuromyelitis optica and logitudinally extensive myelitis. J Neurol 255: 305-307, 2008
7）Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477, 2005
8）Houzen H, Kondo K, Niino M, Horiuchi K, Takahashi T, et al: Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology 89: 1995-2001, 2017
9）Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, et al: Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 11: 501, 2020［doi: 10.3389/fneur.2020.00501］
10）Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, et al: Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology 91: e1642-e1651, 2018［doi: 10.1212/WNL.0000000000006392］
11）Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, et al: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85: 177-189, 2015
12）Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, et al: Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130: 1235-1243, 2007
13）高橋利幸, 狩野俊吾, 池本圭輔, 中島一郎: M23抗原を用いたAQP4Ab ELISA「コスミック」IIキットの基礎的・臨床的検討. 医学と薬学73: 1297-1300, 2016
14）Takano R, Misu T, Takahashi T, Sato S, Fujihara K, et al: Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75: 208-216, 2010
15）Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, et al: Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82: 474-481, 2014
16）Juryńczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, et al: Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry 88: 132-136, 2017
17）Matsumoto Y, Misu T, Mugikura S, Takai Y, Nishiyama S, et al: Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases. J Neurol Neurosurg Psychiatry: jnnp-2020-324818, 2020［doi: 10.1136/jnnp-2020-324818］
18）Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, et al: Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13: 968-974, 2007
19）Kageyama T, Komori M, Miyamoto K, Ozaki A, Suenaga T, et al: Combination of cyclosporine a with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 260: 627-634, 2013
20）Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, et al: Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79: 206-216, 2016
21）Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, et al: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381: 614-625, 2019
22）Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, et al: Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381: 2114-2124, 2019
23）Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, et al: Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19: 298-306, 2020
24）Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, et al: Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394: 1352-1363, 2019
25）Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, et al: CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder. Heliyon 7: e05899, 2021［doi: 10.1016/j.heliyon.2021.e05899］
掲載誌情報
